Pfizer or will usher in the "elephant" turn around, where will the medical representatives go?

[pharmaceutical network industry trends] recently, the problem of employee placement after the merger of Pfizer and mylan has attracted wide attention in the industry According to relevant people's description, the merger of the two companies will probably be completed in mid-2020 After the merger, key talents will be retained, but some employees will have job changes With the adjustment of personnel, Pfizer may have an "elephant" turn For Pfizer's merger, the industry speculated that some of the changed employees, or medical representatives, would leave I found that not long ago, Japanese media reported that Pfizer Japan released relevant policies and raised early retirees About 200 medical representatives over the age of 50 were recruited According to statistics, Pfizer's medical representative team in Japan has remained around 2000 for many years, but in 2018, the number has decreased by 170 So Pfizer is cutting the number of pharmaceutical representatives The industry believes that this is mainly due to the increasing competitive pressure faced by multinational enterprises In fact, it's no surprise that the news of the withdrawal of pharmaceutical representatives is no longer surprising for multinational pharmaceutical companies or local pharmaceutical companies According to the industry analysis, on the one hand, it is the change of salary, on the other hand, it is affected by the occupational environment According to statistics, more than 60% of medical representatives believe that the change of internal strategy and the difficulty of academic promotion caused by policies are the main problems facing the company, and more than 50% of medical representatives believe that they are troubled by the sales of preventive gold in hospitals In terms of the situation of medical representatives in China, influenced by the two vote system, the proportion of controlled drugs, and the 4 + 7 volume purchase, the cost pressure of pharmaceutical enterprises has increased, the cost of sales has been cut down, the cost of traditional academic promotion and hospital promotion has been cut down, the sales with money has lost the living space, and the livelihood of millions of medical representatives is being impacted In this context, medical representatives are accelerating the transformation For example, youshibi has withdrawn the position of pharmaceutical representative earlier, and more pharmaceutical companies are also adjusting their positions According to industry statistics, in 2018, the turnover rate of medical representatives in China increased significantly, of which 70% are ready for transformation and 20% are already in transformation Entering 2019, the days of medical representatives are more difficult A few days ago, the notice on printing and distributing the key points of rectifying unhealthy practices in the field of medicine purchase and sale and medical services in 2019 issued by China has been successively implemented in various places The key points of this work once again stipulate the implementation of the registration and filing management of medical representatives in the hospital, and standardize the reception system of medical representatives in the hospital "Hospital registration and filing management of pharmaceutical representatives" means that pharmaceutical manufacturers (listing license holders) shall disclose the filing information of their pharmaceutical representatives, and pharmaceutical representatives must receive training in relevant laws and regulations, professional ethics, professional knowledge, etc At the same time, the medical institutions shall establish and improve the reception process of the medical representatives in the hospital, ensure that the behaviors of the medical representatives in the hospital can be recorded, monitored and disclosed, improve the medical service environment, strengthen the internal inspection and monitoring system of the medical institutions, and strongly advise the medical representatives who do not work according to the requirements of the hospital to leave The key points of this work once again emphasize the registration and filing management of medical representatives in the hospital, which also shows that the standardization of medical representatives in China has been further improved According to the industry, the 3 million medical representatives across the country are facing policy pressure and will not be easy in the future In this case, the transformation is earlier, and the medical representatives may be transformed into out of hospital sales or become a new way.